Venus Medtech (Hangzhou) Inc.

OTCPK:VMTH.F Stock Report

Market Cap: US$315.0m

Venus Medtech (Hangzhou) Management

Management criteria checks 3/4

Venus Medtech (Hangzhou)'s CEO is Lin Haosheng Lim, appointed in Dec 2016, has a tenure of 7.58 years. total yearly compensation is CN¥57.00K, comprised of 84.2% salary and 15.8% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $881.96. The average tenure of the management team and the board of directors is 2.3 years and 2.2 years respectively.

Key information

Lin Haosheng Lim

Chief executive officer

CN¥57.0k

Total compensation

CEO salary percentage84.2%
CEO tenure7.6yrs
CEO ownership0.0003%
Management average tenure2.3yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Lin Haosheng Lim's remuneration changed compared to Venus Medtech (Hangzhou)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023CN¥57kCN¥48k

-CN¥704m

Sep 30 2023n/an/a

-CN¥956m

Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥1mCN¥1m

-CN¥1b

Sep 30 2022n/an/a

-CN¥759m

Jun 30 2022n/an/a

-CN¥461m

Mar 31 2022n/an/a

-CN¥417m

Dec 31 2021CN¥1mCN¥694k

-CN¥374m

Compensation vs Market: Lin Haosheng's total compensation ($USD7.84K) is below average for companies of similar size in the US market ($USD2.46M).

Compensation vs Earnings: Lin Haosheng's compensation has been consistent with company performance over the past year.

CEO

Lin Haosheng Lim (49 yo)

7.6yrs

Tenure

CN¥57,000

Compensation

Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Executive Director at Ve...

Leadership Team

NamePositionTenureCompensationOwnership
Hou-Sen Lim
GM, COO & CTO and Executive Director7.6yrsCN¥57.00k0.00028%
$ 882.0
Liu Meirong
VP & Executive Director1.5yrsCN¥1.18mno data
Liqiao Ma
VP of clinical medicine & Executive Directorless than a yearCN¥46.00k0.0084%
$ 26.6k
Fei Wang
Chief Financial Officerless than a yearno datano data
Joyce Heo
Director of Sales2.3yrsno datano data
Christopher Richardson
Head of U.S. Operations5yrsno datano data
Amir Gross
Head of Venus Global Heart Valve Innovation Center2.3yrsno datano data
Shakeel Osman
Head of International Congenital Heart Disease Business2.3yrsno datano data
Wai Chiu Wong
Company Secretary3.5yrsno datano data

2.3yrs

Average Tenure

48.5yo

Average Age

Experienced Management: VMTH.F's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hou-Sen Lim
GM, COO & CTO and Executive Directorless than a yearCN¥57.00k0.00028%
$ 882.0
Liu Meirong
VP & Executive Director1.5yrsCN¥1.18mno data
Liqiao Ma
VP of clinical medicine & Executive Directorless than a yearCN¥46.00k0.0084%
$ 26.6k
Martin B. Leon
Member of Advisory Boardno datano datano data
Chaim Lotan
Member of Global Advisory Board4.5yrsno datano data
Ting Yuk Wu
Independent Chairman of the Board5.7yrsCN¥360.00kno data
Chi Wai Suen
Independent Non-Executive Director5yrsCN¥360.00kno data
Wei Wang
Shareholders Representative Supervisor5.7yrsno datano data
Scott Lim
Member of Global Advisory Board4.5yrsno datano data
Min Shao
Employee Representative Supervisor1.9yrsno datano data
Zhang Ao
Non-Executive Director1.5yrsno datano data
Yue Li
Shareholders Representative Supervisor2.2yrsno datano data

2.2yrs

Average Tenure

48.5yo

Average Age

Experienced Board: VMTH.F's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/06 01:05
End of Day Share Price 2024/04/08 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Venus Medtech (Hangzhou) Inc. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wai Chak YuenBOCI Research Ltd.
Jin ZhangChina International Capital Corporation Limited
Haoyuan ZhangChina Merchants Securities (HK) Co., Ltd